XTH31 Antibody

What is XTH31 and why would researchers need antibodies against it?

XTH31 is a member of the Xyloglucan Endotransglucosylase-Hydrolase (XTH) family in Arabidopsis thaliana. It primarily exhibits xyloglucan endohydrolase (XEH) activity with an XEH:XET activity ratio of >5000:1 as demonstrated through heterologous expression in Pichia pastoris . XTH31 plays a crucial role in modifying xyloglucan in the cell wall, affecting aluminum sensitivity by modulating cell wall xyloglucan content and aluminum binding capacity .

Researchers require XTH31 antibodies for several critical applications:

• Detecting native protein expression levels in different tissues

• Confirming subcellular localization results obtained from GFP fusion studies

• Studying protein-protein interactions, particularly with XTH17

• Examining post-translational modifications

• Analyzing changes in protein levels in response to environmental stresses

How does XTH31 differ from other XTH family members?

XTH31 belongs to Group IIIA of the XTH family, one of only two members (alongside XTH32) predicted to have XEH activity as their primary function . Unlike most XTHs that predominantly exhibit XET activity, XTH31 shows remarkably higher XEH activity. This functional difference is reflected in its sequence, which contains XET-like conserved sequences similar to bacterial β-glucanases, particularly the DEIDF/IEFLG sequence (with Val replacing the first Ile in XTH31) .

When producing antibodies against XTH31, researchers should consider these unique sequence features:

• The active site containing the DEIDIEFLG-like sequence

• The N-terminal signal peptide region (first 19 amino acids)

• Unique epitopes that differ from other XTH family members

What tissue preparation methods work best for XTH31 antibody immunohistochemistry?

For optimal tissue preparation when using XTH31 antibodies:

• Fixation: Use 4% paraformaldehyde in PBS for 2-4 hours at room temperature or overnight at 4°C

• Tissue sectioning: For root samples, particularly the elongation zone where XTH31 is highly expressed, prepare 5-10 μm thick sections

• Antigen retrieval: Consider citrate buffer (pH 6.0) treatment if necessary

• Blocking: Use 3-5% BSA in PBS with 0.1% Triton X-100

• Primary antibody incubation: Optimal dilution must be determined empirically

When designing experiments, focus particularly on the root elongation zone and young expanding leaves where XTH31 expression is most prominent .

How can XTH31 antibodies help investigate aluminum resistance mechanisms?

XTH31 knockout mutants (xth31) demonstrate increased aluminum resistance through reduced xyloglucan accumulation in the cell wall, which leads to decreased aluminum binding capacity . Researchers can utilize XTH31 antibodies to:

• Compare XTH31 protein levels between wild-type and aluminum-resistant plant varieties

• Track changes in XTH31 protein abundance during aluminum exposure (correlating with observed transcriptional downregulation)

• Examine tissue-specific responses using immunohistochemistry

• Investigate post-translational modifications that might be triggered by aluminum stress

Research indicates that XTH31 transcript accumulation is strongly downregulated by aluminum treatment . Using antibodies to measure protein levels would reveal whether this transcriptional change translates to reduced protein abundance and the timeline of this response.

What approaches can be used to study XTH31-XTH17 interactions with antibodies?

XTH17 has been shown to bind to XTH31 in vitro and in vivo, and T-DNA insertional mutants of XTH17 exhibit elevated aluminum resistance . Researchers can employ the following antibody-based techniques to study this interaction:

• Co-immunoprecipitation (Co-IP):

  • Use anti-XTH31 antibodies to pull down protein complexes

  • Detect XTH17 in the immunoprecipitate using anti-XTH17 antibodies

  • Compare results with reciprocal Co-IP using anti-XTH17 antibodies

• Proximity Ligation Assay (PLA):

  • Utilize both anti-XTH31 and anti-XTH17 antibodies

  • Visualize protein interactions in situ with single-molecule resolution

  • Map interaction sites within specific subcellular compartments

• FRET-based immunofluorescence:

  • Use fluorophore-conjugated antibodies to detect potential energy transfer

  • Confirm physical proximity of proteins in their native environment

How can XTH31 antibodies confirm subcellular localization findings?

GFP fusion studies have shown that XTH31 localizes to the plasma membrane, with this localization dependent on its N-terminal signal peptide . Researchers can validate and extend these findings using antibody-based approaches:

• Immunogold electron microscopy:

  • Provides nanometer-scale resolution of protein localization

  • Can distinguish between plasma membrane, cell wall, and endoplasmic reticulum localization

  • Requires careful fixation to preserve membrane structures

• Cell fractionation with Western blotting:

  • Separate cellular components (membrane, cytosol, cell wall)

  • Probe fractions with anti-XTH31 antibodies

  • Compare distribution with known compartment markers

• Super-resolution immunofluorescence microscopy:

  • Techniques like STORM or PALM provide resolution beyond the diffraction limit

  • Can visualize protein distribution at the plasma membrane-cell wall interface

These approaches would help confirm the finding that XTH31 is "well positioned for catalyzing either this process or the partial hydrolysis of newly secreted xyloglucans" .

What epitope selection strategies work best for XTH31 antibody development?

When developing antibodies against XTH31, careful epitope selection is crucial:

• Signal peptide considerations:

  • The N-terminal signal peptide (first 19 amino acids) is essential for plasma membrane localization

  • Antibodies targeting this region may not recognize mature, processed protein

  • For detecting processed protein, choose epitopes downstream of the signal peptide

• Active site accessibility:

  • The DEIDIEFLG-like sequence contains the catalytic site

  • Antibodies targeting this region may interfere with activity assays

  • Consider structural models to identify surface-exposed regions

• Specificity concerns:

  • Select regions with minimal homology to XTH32 (the other Group IIIA member)

  • Avoid conserved domains shared across the XTH family

  • Consider peptide-based immunization targeting unique regions

Multiple epitope targeting might be necessary to develop antibodies suitable for different applications (Western blotting vs. immunoprecipitation vs. immunohistochemistry).

What controls are essential for validating XTH31 antibody specificity?

To ensure antibody specificity, researchers should implement the following controls:

• Genetic controls:

  • The T-DNA insertion mutant (xth31) described in the literature provides an ideal negative control

  • Overexpression lines can serve as positive controls

  • Consider testing in xth32 mutants to confirm no cross-reactivity

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Should eliminate specific signal

  • Use unrelated peptide as negative control

• Recombinant protein validation:

  • Test against heterologously expressed XTH31 (as described in Pichia pastoris system)

  • Include related XTH family members to assess cross-reactivity

• Western blot validation:

  • Confirm single band at expected molecular weight

  • Verify band disappearance in xth31 mutant

  • Check for different band patterns in various tissues (correlating with known expression patterns)

How can researchers optimize XTH31 antibody use in analyzing aluminum stress responses?

When using XTH31 antibodies to study aluminum stress responses:

• Experimental timing considerations:

  • XTH31 transcript levels are rapidly downregulated upon aluminum treatment

  • Collect samples at multiple time points (15 min, 30 min, 1 hr, 3 hr, 6 hr)

  • Compare protein persistence with transcript reduction

• Tissue-specific analysis:

  • Focus on root elongation zone where XTH31 is highly expressed

  • Consider microdissection to isolate specific regions

  • Compare with other tissues as controls

• Quantification approaches:

  • Use quantitative Western blotting with appropriate loading controls

  • Consider ELISA-based quantification for higher sensitivity

  • Correlate protein levels with in vivo XET action measurements

• Combinatorial analysis:

  • Pair antibody studies with cell wall composition analysis

  • Correlate XTH31 levels with xyloglucan content measurements

  • Link to aluminum accumulation data from the same tissues

This approach would provide comprehensive insights into how "XTH31 affects Al sensitivity by modulating cell wall xyloglucan content and Al binding capacity" .

How should researchers address potential cross-reactivity with other XTH family members?

Cross-reactivity is a significant concern when working with protein families like XTHs. To address this:

• Pre-absorption strategies:

  • Express recombinant versions of closely related XTHs

  • Pre-absorb antibodies against these proteins

  • Test resulting antibody for improved specificity

• Epitope mapping:

  • Determine the exact epitope recognized by the antibody

  • Compare with sequence alignments of other XTH family members

  • Predict potential cross-reactivity based on sequence similarity

• Western blot pattern analysis:

  • Compare banding patterns between wild-type and various xth mutants

  • Look for subtle mobility shifts that might indicate different XTH proteins

  • Consider 2D gel electrophoresis to separate based on both size and charge

What methodological adaptations are needed when studying XTH31-XTH17 complexes?

Based on evidence that XTH17 can bind to XTH31 in vitro and in vivo , researchers should consider these methodological adaptations:

• Sequential immunoprecipitation:

  • First IP with anti-XTH31

  • Elute under mild conditions

  • Second IP with anti-XTH17

  • Analyze resulting complexes

• Crosslinking considerations:

  • Use membrane-permeable crosslinkers to stabilize complexes

  • Compare results with and without crosslinking

  • Consider proximity-dependent biotinylation approaches

• Native PAGE analysis:

  • Preserve protein complexes during extraction

  • Compare migration patterns with denatured samples

  • Consider blue native PAGE for membrane protein complexes

• Quantitative co-localization:

  • Use dual immunofluorescence with both antibodies

  • Employ rigorous co-localization statistical analysis

  • Compare results in different cellular regions and treatments

Understanding this interaction is particularly important given that "loss of XTH31 results in remarkably reduced in vivo xyloglucan endotransglucosylase (XET) action" , suggesting functional interactions between these proteins.

How might XTH31 antibodies contribute to understanding cell wall remodeling during development?

XTH31 expression is "prominent in regions where cellular expansion is likely to occur" . Researchers can utilize XTH31 antibodies to:

• Create high-resolution developmental expression maps:

  • Track protein levels throughout plant development

  • Correlate with cellular expansion rates

  • Compare with other cell wall remodeling enzymes

• Investigate mechanical stress responses:

  • Apply controlled mechanical stimuli to tissues

  • Monitor XTH31 redistribution or abundance changes

  • Link to local cell wall modifications

• Study hormone response pathways:

  • Examine how growth hormones affect XTH31 protein levels

  • Compare with transcriptional changes

  • Explore post-translational regulation mechanisms

These approaches would extend our understanding beyond the current findings that "the loss of XTH31 function results in remarkably lower in vivo XET action and extractable XET activity, has a lower xyloglucan content, and exhibits slower elongation" .

What role might post-translational modifications play in regulating XTH31 function?

While current research focuses primarily on XTH31 expression and localization, antibodies could reveal important post-translational regulation:

• Phosphorylation analysis:

  • Use phospho-specific antibodies if key sites are identified

  • Compare phosphorylation status under different stresses

  • Link modifications to enzyme activity changes

• Glycosylation investigation:

  • Detect potential glycosylation through mobility shifts

  • Use glycosidase treatments to confirm modifications

  • Explore impact on protein stability and activity

• Degradation pathway studies:

  • Monitor protein turnover rates

  • Identify conditions that trigger degradation

  • Examine ubiquitination or other degradation signals

These approaches would provide deeper insights into the regulatory mechanisms that control XTH31 function beyond transcriptional control.